Evidence map›Paper›PMID 37452961›Full record

Trial reportAdvances in therapy2023

Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study.

Masaru Inatani, Yusuke Orii, Kentaro Iwasaki, Shogo Arimura, Hiromi Sunagawa, Minako Shiokawa, Kenji Inoue, Takuto Sakono, Takato Sakono, Rika Kuwamura and 40 more

Open access · hybridAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Management and outcomes of primary open-angle glaucoma.Journal of family medicine and primary care · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors at 12 institutions in 1 country.

Masaru InataniFaculty of Medical Sciences, Department of Ophthalmology, University of Fukui, 23-3 Shimoaizuki, Matsuoka, Eiheiji, Yoshida, Fukui, 910-1193, Japan. inatani@u-fukui.ac.jp.ORCID http://orcid.org/0000-0003-0896-996X
Yusuke OriiFaculty of Medical Sciences, Department of Ophthalmology, University of Fukui, 23-3 Shimoaizuki, Matsuoka, Eiheiji, Yoshida, Fukui, 910-1193, Japan.
Kentaro IwasakiFaculty of Medical Sciences, Department of Ophthalmology, University of Fukui, 23-3 Shimoaizuki, Matsuoka, Eiheiji, Yoshida, Fukui, 910-1193, Japan.
Shogo ArimuraFaculty of Medical Sciences, Department of Ophthalmology, University of Fukui, 23-3 Shimoaizuki, Matsuoka, Eiheiji, Yoshida, Fukui, 910-1193, Japan.
Hiromi SunagawaInouye Eye Hospital, Tokyo, Japan.
Minako ShiokawaInouye Eye Hospital, Tokyo, Japan.
Kenji InoueInouye Eye Hospital, Tokyo, Japan.
Takuto SakonoIgo Ophthalmic Clinic, Kagoshima, Japan.
Takato SakonoIgo Ophthalmic Clinic, Kagoshima, Japan.
Rika KuwamuraFukushima Eye Clinic, Osaka, Japan.
Akiko YoshidaFukushima Eye Clinic, Osaka, Japan.
Junko OiFukushima Eye Clinic, Osaka, Japan.
Yasuaki KuwayamaFukushima Eye Clinic, Osaka, Japan.
Kiyoshi KanoFukushima Eye Clinic, Osaka, Japan.
Noriaki KidoMidorino Eye Clinic, Hyogo, Japan.
Akiko MatsuyamaOzaki Eye Hospital, Miyazaki, Japan.
Mineo OzakiOzaki Eye Hospital, Miyazaki, Japan.
Hideki AbeMusashi Dream Clinic, Osaka, Japan.
Chizuru InoueMusashi Dream Clinic, Osaka, Japan.
Satoko NakagawaMusashi Dream Clinic, Osaka, Japan.
Kunihiro MusashiMusashi Dream Clinic, Osaka, Japan.
Akiyasu KanamoriKanamori Eye Clinic, Hyogo, Japan.
Jinhee LeeMiyata Eye Hospital, Miyazaki, Japan.
Shinichiro OtaniMiyata Eye Hospital, Miyazaki, Japan.
Ryota AokiDepartment of Ophthalmology, Saneikai Tsukazaki Hospital, Hyogo, Japan.
Hirotaka TanabeDepartment of Ophthalmology, Saneikai Tsukazaki Hospital, Hyogo, Japan.
Shunsuke NakakuraDepartment of Ophthalmology, Saneikai Tsukazaki Hospital, Hyogo, Japan.
Katsuyoshi SuzukiSuzuki Eye Clinic, Yamaguchi, Japan.
Takeshi SagaraSagara Eye Clinic, Yamaguchi, Japan.
Yoshiaki SaitoSaito Eye Clinic, Ishikawa, Japan.
Motoyasu SameshimaSameshima Eye Clinic, Kagoshima, Japan.
Mai UrahashiFaculty of Life Sciences, Department of Ophthalmology, Kumamoto University, Kumamoto, Japan.
Fumika Watanabe-KitamuraFaculty of Life Sciences, Department of Ophthalmology, Kumamoto University, Kumamoto, Japan.
Toshihiro InoueFaculty of Life Sciences, Department of Ophthalmology, Kumamoto University, Kumamoto, Japan.
Fumie KagayaKagoshima Miyata Eye Clinic, Kagoshima, Japan.
Yusuke MuraiDivision of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Hyogo, Japan.
Sotaro MoriDivision of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Hyogo, Japan.
Kaori UedaDivision of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Hyogo, Japan.
Takuji KurimotoDivision of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Hyogo, Japan.
Yuko Yamada-NakanishiDivision of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Hyogo, Japan.
Makoto NakamuraDivision of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Hyogo, Japan.
Takehiro YamashitaYamashita Eye Clinic, Kagoshima, Japan.
Sosuke IshiyamaHayashi Eye Hospital, Fukuoka, Japan.
Shinichi ManabeHayashi Eye Hospital, Fukuoka, Japan.
Keiko TakakiHayashi Eye Hospital, Fukuoka, Japan.
Ken HayashiHayashi Eye Hospital, Fukuoka, Japan.
Akiko IshidaFaculty of Medicine, Department of Ophthalmology, Shimane University, Shimane, Japan.
Aika TsutsuiFaculty of Medicine, Department of Ophthalmology, Shimane University, Shimane, Japan.
Kaoru ManabeFaculty of Medicine, Department of Ophthalmology, Shimane University, Shimane, Japan.
Masaki TanitoFaculty of Medicine, Department of Ophthalmology, Shimane University, Shimane, Japan.
Kobe University · JPMiyata Eye Hospital · JPTokushima Breast Care Clinic · JPHayashi Eye Hospital · JPMusashi University · JPShimane University · JPUniversity of Fukui · JPInouye Eye Hospital · JPKumamoto University · JPHara Eye Hospital · JPMinamiaoyama Eye Clinic · JPSuzuki (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis multicenter, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and tolerability of fixed combinations of 0.1% brimonidine/0.5% timolol (BTFC) versus 1% dorzolamide/0.5% timolol (DTFC) as adjunctive therapies to prostaglandin analogues.

methodsA total of 110 patients with open-angle glaucoma or ocular hypertension previously treated with prostaglandin analogue monotherapy were randomized to receive either BTFC or DTFC as adjunctive therapy for 8 weeks. These patients were then crossed over to the alternative treatment arm for another 8 weeks. The reduction in intraocular pressure (IOP) (primary outcome), occurrence of adverse events, ocular discomfort after instillation, and patient preference (secondary outcomes) were recorded through patient interviews.

resultsBTFC instillation for 8 weeks reduced IOP by 3.55 mmHg, demonstrating non-inferiority to DTFC instillation (3.60 mmHg; P < 0.0001, mixed-effects model). Although adverse events were rare with both combinations, patients reported greater discomfort with DTFC than with BTFC (P < 0.0001). More patients preferred BTFC (P < 0.0001) over DTFC, as BTFC caused minimal or no eye irritation.

conclusionAs BTFC offered better tolerability than DTFC with comparable reduction in IOP, we recommend it as an alternative for patients who experience ocular discomfort with DTFC-prostaglandin analogue combination therapy. TRIAL REGISTRATION NUMBER: jRCTs051190125.

Indexed as

Glaucoma, Open-AngleTimololAntihypertensive AgentsBrimonidine TartrateCross-Over StudiesDrug CombinationsHumansIntraocular PressureOphthalmic SolutionsProstaglandins, SyntheticSulfonamidesThiophenesAntihypertensive AgentsBrimonidine TartratedorzolamideDrug CombinationsOphthalmic SolutionsProstaglandins, SyntheticSulfonamidesThiophenesTimololAibetaBrimonidineCombiganCosoptCrossoverDorzolamideGlaucomaIntraocular pressureRandomized clinical trialTimolol

Identifiers

PMID37452961
PMCPMC10427524
OpenAlexW4384406740

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.